NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · VAXX · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vaxxinity, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vaxxinity, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.12. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vaxxinity, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.15+6.25% vs estimate |
| $0.00 |
| Q2 2022 | Aug 11, 2022 | -$0.14+63.16% vs estimate | $0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$410.91+$3.81 (+0.94%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 10.99% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
DKK 635.00-DKK 15.00 (-2.31%)
Strategic Partners A/S’s quoted price sits in the lower half of its reported 52-week range, 32.88% below the high.
$0.00+$0.00 (0.0%)
PaxMedica, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 96.5% below the high.
